Clinical and Analytical Performance of ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults.

Clinical and Analytical Performance of ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults.

Publication date: Jan 05, 2024

Saliva is a promising matrix with several purposes. Our aim is to verify if salivary anti-SARS-CoV-2 antibody determination is suitable for monitoring immune responses. One hundred eighty-seven subjects were enrolled at University-Hospital Padova: 105 females (56. 1%) and 82 males (43. 9%), 95 (50. 8%) children and 92 (49. 2%) adults. Subjects self-collected saliva using Salivette; nineteen subjects collected three different samples within the day. A serum sample was obtained for all individuals. The N/S anti-SARS-CoV-2 salivary IgG (sal-IgG) and serum anti-SARS-CoV-2 S-RBD IgG (ser-IgG) were used for determining anti-SARS-CoV-2 antibodies. The mean (min-max) age was 9. 0 (1-18) for children and 42. 5 (20-61) for adults. Of 187 samples, 63 were negative for sal-IgG (33. 7%), while 7 were negative for ser-IgG (3. 7%). Spearman’s correlation was 0. 56 (p < 0. 001). Sal-IgG and ser-IgG levels were correlated with age but not with gender, comorbidities, prolonged therapy, previous SARS-CoV-2 infection, or time from last COVID-19 infection/vaccination. The repeatability ranged from 23. 8% (7. 4 kAU/L) to 4. 0% (3. 77 kAU/L). The linearity of the assay was missed in 4/6 samples. No significant intrasubject differences were observed in sal-IgG across samples collected at different time points. Sal-IgG has good agreement with ser-IgG. Noninvasive saliva collection represents an alternative method for antibody measurement, especially in children.

Open Access PDF

Concepts Keywords
Eighty adults
Females children
Spearman ELISA
University salivary samples
Vaccination SARS-CoV-2 antibodies

Semantics

Type Source Name
disease IDO assay
drug DRUGBANK Serine
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO time
disease MESH infection
disease VO vaccination
disease VO organization
disease MESH emergency
disease MESH morbidity
disease MESH viral infection
disease MESH reinfection
drug DRUGBANK Coenzyme M
disease VO vaccine
disease IDO cell
drug DRUGBANK Pentaerythritol tetranitrate
disease VO effective
disease VO population
disease IDO history
disease VO device
disease VO mouth
disease IDO blood
disease VO USA
disease VO protocol
disease MESH rheumatic diseases
disease MESH inflammatory bowel diseases
disease MESH metabolic diseases
disease MESH hypothyroidism
disease VO immunization
disease MESH clinical relevance
disease MESH syndrome
disease VO nose
drug DRUGBANK Aspartame
disease VO age
disease VO vaccinated
disease VO document
disease VO effectiveness
disease IDO contact tracing
disease VO Comirnaty
disease MESH Allergy
disease MESH Asthma
pathway KEGG Asthma
disease VO efficient
disease MESH Common Variable Immunodeficiency
disease MESH immunocompromised patients
disease VO dose
disease MESH breakthrough infection

Original Article

(Visited 1 times, 1 visits today)